What are the Historical Developments and Current Growth Metrics of the Veterinary Active Pharmaceutical Ingredients Manufacturing Market?
The veterinary active pharmaceutical ingredients manufacturing market has seen considerable growth due to a variety of factors.
• The market size for the production of veterinary active pharmaceutical ingredients has seen significant growth in the past few years. It was projected to expand from a worth of $7.46 billion in 2024 to a value of $8.05 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.9%. Factors contributing to growth during the historic period included an increase in pet adoption, rigorous regulatory norms, a heightened emphasis on animal nutrition, investment in research and development, and global economic expansion.
What Does Future Hold for The Veterinary Active Pharmaceutical Ingredients Manufacturing Market in the Coming Years?
The Veterinary Active Pharmaceutical Ingredients Manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The market for manufacturing veterinary active pharmaceutical ingredients is projected to witness substantial growth in the forthcoming years, with its value likely to reach $11.19 billion in 2029 at an 8.6%.
compound annual growth rate (CAGR). The predicted growth during the forecast period can be tied back to progress in personalized veterinary medicine, globalization and expansion of the market, emphasising more on regulatory compliance, increasing focus on animal welfare, improvements in drug delivery systems, and an escalating demand for nutraceuticals. The key trends for the forecast period are expected to be advancements in manufacturing processes, a rising trend of outsourcing API manufacturing, a move towards biotechnological APIs, digitalization and automation in manufacturing, and globalization of the veterinary API market.
What Are The Primary Growth Drivers In The Veterinary Active Pharmaceutical Ingredients Manufacturing Market?
The rise in pet ownership is predicted to spur the expansion of the veterinary active pharmaceutical ingredients production market. Those who own or adopt a pet animal are referred to as pet owners. They cater to the necessary healthcare needs of their pets, which in turn boosts the demand for veterinary medications. For example, in 2022, data from Animal Medicines Australia, an Australian non-governmental organization, revealed a substantial growth in pet ownership with the count reaching 28,730.8 in 2022, higher from 39% in 2021. This indicates a 24% rise, marking a significant upward swing in pet adoption and healthcare spending. The uptick in pet ownership underlines the climbing popularity of pets in Australian homes. Therefore, the increasing population of pet owners fuels the market for veterinary active pharmaceutical ingredients production.
What Is The Segmentation Of The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market?
The veterinary active pharmaceutical ingredients manufacturing market covered in this report is segmented –
1) By Product: Antiparasitic, Anti-Infectives, Vaccines, NSAIDs
2) By Service Type: In House, Contract Outsourcing
3) By Synthesis Type: Chemical Based API, Biological API, Highly Potent API
Subsegments:
1) By Antiparasitic: Endectocides, Anthelmintics, Antiprotozoals
2) By Anti-Infectives: Antibiotics, Antifungals, Antivirals
3) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines
4) By NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Non-Selective NSAIDs, COX-2 Inhibitors
Pre-Book The Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Veterinary Active Pharmaceutical Ingredients Manufacturing Market Landscape?
In the veterinary active pharmaceutical ingredient manufacturing field, the key trend gaining traction is product innovation. To uphold their market standing, the dominant companies are focusing on producing innovative products. For instance, Zoetis Inc., an American company specializing in drugs for pets and livestock, received US FDA approval in January 2022 for Solensia (frunevetmab injection), intended to manage osteoarthritis (OA) pain in cats. Solensia is currently the only injectable monoclonal antibody treatment for feline OA pain that has received approval in the U.S., and it functions by targeting and neutralizing nerve growth factor (NGF), a primary cause of osteoarthritis pain.
Who Are the Key Players In The Veterinary Active Pharmaceutical Ingredients Manufacturing Market?
Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market include:
• Alivira Animal Health Limited
• Excel Industries Limited
• Ofichem Group B.V.
• Jiangsu Lingyun Pharmaceutical Co. Ltd.
• SUANFARMA S.A.
• NGL Fine-Chem Limited
• FIS - Fabbrica Italiana Sintetici S.p.A.
• Lupin Limited
• Aurobindo Pharma Limited
• Saneca Pharmaceuticals AS
• Neuland Laboratories Limited
• Divi's Laboratories Limited
• Zoetis Inc.
• Grupo Indukern S.L.
• Sequent Scientific Limited
• Chempro Pharma Private Limited
• AMGIS Lifescience Ltd.
• Huvepharma AD
• Vetpharma Animal Health S.L.
• Qilu Pharma Spain S.A.
• INDUKERN Chemie AG
• Chemopharma S.A.
• Norbrook Laboratories Limited
• Ceva Santé Animale S.A.
• Vetoquinol S.A.
• Virbac S.A.
What Are The Regional Insights Into The Veterinary Active Pharmaceutical Ingredients Manufacturing Market?
North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2024. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
